Industry Overview

The U.S. physical therapy and occupational therapy industry has reached an inflection point in 2026. After several years of clinical labor shortages, wage inflation, and reimbursement pressure, the sector is moving into a clear phase of structured growth and consolidation. The U.S. physical therapy market, valued at roughly $49.5 billion at the start of the decade, is projected to reach $61.7 billion by 2030, a 4.6% compound annual growth rate.

That growth is anchored by demographics that are not going to reverse. By 2030, the entire baby boomer generation will be over 65 and will make up roughly 20% of the U.S. population. That translates into rising demand for joint mobility, fall prevention, and post-surgical rehabilitation. As the broader healthcare system continues moving toward value-based care, physical and occupational therapy are increasingly recognized as cost-effective interventions that reduce surgical volume and chronic pain prescription dependence.

For owners considering a sale, the important distinction is that PT and OT, while often grouped together, attract different buyers. Physical therapy is biomechanically focused: orthopedic recovery, post-surgical rehab, workers' compensation, sports medicine. PT employment is projected to grow 28% by the end of the decade, with average clinician compensation around $97,720. Occupational therapy blends physical rehabilitation with cognitive and behavioral elements, focusing on activities of daily living, fine motor skills, and sensory integration. OT employment is projected to grow 24%, with average compensation around $93,180. As we will cover later in this report, OT clinics, particularly in pediatrics, are being acquired through a different channel than traditional outpatient PT.

The headwinds are real but well understood. Clinician burnout remains the dominant operational risk, with 68% of therapists reporting emotional burnout, and that figure climbs to 79% for clinicians under 30. Therapists are spending up to three hours per day on documentation outside of patient-facing work. Clinics that have responded by dropping low-reimbursing payers, renegotiating contracts, and shifting toward workers' compensation and personal injury are now positioned exceptionally well for an exit.

M&A Activity & Deal Volume

The 2026 deal market looks nothing like 2022 to 2024. Following years of subdued velocity, driven by elevated interest rates, margin pressure, and questions about virtual MSK platforms, transaction volume has clearly recovered. The signal that turned sentiment came in mid-2025, when U.S. Physical Therapy (USPH) reported earnings of $0.81 per share against a $0.71 estimate, telling the broader investment community that the structural pressures on outpatient rehab were easing.

Heading into Q1 2026, the broader healthcare M&A market is riding a 40% year-over-year increase in announced deal value, and provider services deal volume is up more than 10%. In the lower-middle market specifically, transactions are concentrated rather than indiscriminate. Buyers are not running speculative roll-ups. They are executing targeted bolt-on acquisitions in geographies that fit existing platforms, and they are paying real money for clinics with clean financials and diversified payer mixes.

Recent transactions that illustrate the current playbook:

• Intune Physical Therapy (backed by Highland Ventures) acquired Nesin Physical Therapy, expanding its regional footprint.
• Accord Asset Partners, in collaboration with Paras Capital, acquired WestStar Physical Therapy Network in Southern California. The target's specialization in workers' compensation and personal injury was central to the thesis, insulating the platform from Medicare rate volatility.
• U.S. Physical Therapy acquired a 50% interest in an eight-clinic practice generating $8.0 million in revenue, plus a 70% interest in a $7.0 million industrial injury prevention business in Q1 2026 alone.

The pediatric occupational therapy story is separate and arguably more aggressive. Independent pediatric OT clinics are rarely acquired as standalone assets. They are absorbed into multidisciplinary developmental platforms, often anchored by autism and ABA services. Recent activity:

• General Atlantic acquired Ally Pediatric Therapy, integrating its speech, OT, and feeding services into ACES ABA, which now operates 92 locations across seven states.
• Aquitaine Capital acquired KidsChoice, an Oklahoma-based pediatric therapy provider.
• Renovus Capital Partners absorbed Autism ETC into its Behavioral Framework platform.

At the macro level, transactions like Ascension's $3.9 billion acquisition of AmSurg, Knighthead Capital Management's activity around ATI Physical Therapy, and Optum's integration of Amedisys point to a clear directional move toward scale across outpatient and post-acute care. For an owner of a $2 million to $10 million PT or OT clinic, the practical implication is that you are now selling into a market where the buyers above you are themselves consolidating.

Buyer Landscape

The buyer universe in 2026 sorts cleanly into two camps. Both want platform-ready clinics, but their underwriting and post-close playbooks differ.

Strategic Consolidators

Strategic acquirers are publicly traded operators or mature PE-backed platforms chasing localized density, regional payer leverage, and fixed-cost absorption across compliance, billing, and HR. The names that matter: Select Medical (over 1,900 locations and integrated specialty hospitals), ATI Physical Therapy, Athletico, Upstream Rehabilitation, and U.S. Physical Therapy. Both Athletico and Upstream are sitting on substantial PE capital and are actively bidding against each other for established regional chains, which is part of why multiples have firmed.

USPH is the cleanest example of disciplined strategic consolidation. The company runs roughly 783 clinics across 44 states with a market cap above $1.4 billion. Its acquisition model is partnership-first: USPH typically buys 51% to 70% majority stakes and uses performance-based earnouts to keep founder skin in the game. That structure is increasingly the template across the strategic buyer set.

Private Equity

PE in 2026 looks different than PE in 2019. Higher cost of capital and longer hold timelines have killed the indiscriminate roll-up. Sponsors are now prioritizing two specific theses:

• Tech-enabled care delivery. Platforms that have integrated AI-driven scheduling, telehealth, automated utilization management, and modern revenue cycle tools. The thesis is that scalable digital infrastructure expands EBITDA margin without proportional headcount growth.
• Multidisciplinary pediatric and behavioral health. Combined autism, ABA, speech, OT, and PT platforms generate strong recurring revenue, capture the full developmental care continuum, and are highly defensible.

For an independent owner, the practical signal is this: clean financial data, modern EMR adoption, and demonstrated therapist productivity through technology are no longer optional. They are how you get a private equity firm to write you a real offer.

Financial Benchmarks

The fundamental unit of revenue in PT and OT is the billable visit. Productivity and throughput, more than any other operational metric, drive enterprise value. Buyers are running detailed Quality of Earnings analyses to determine whether your profitability is sustainable or whether it is being borrowed from your therapists' future tenure.

The healthy operating range for clinician productivity sits between 75% and 85%. This is the bandwidth where therapists are billing efficiently while still preserving time for documentation and care coordination. Clinics running at 95% productivity, where a therapist gets roughly 24 minutes off in an eight-hour shift, get flagged in diligence as burnout-driven mills. That is a discount, not a premium.

An optimized clinician should be running 11 to 14 visits per day at 3.49 to 3.82 billable units per visit. At a blended $100 reimbursement per visit, an optimized therapist conducting 11 visits per day across a five-day week generates roughly $19,250 in weekly revenue, which annualizes to between $150,000 and $250,000 per FTE. The clinic-level operating margin range that buyers are paying for is 10% to 15%, with larger consolidators pushing higher. USPH reported an adjusted PT margin of 16.1% in Q1 2026.

Reimbursement and Payer Mix

Payer mix is the single biggest risk variable buyers underwrite. Practices heavily reliant on Medicare are subject to volatile policy shifts. On October 31, 2025, CMS issued the final 2026 Medicare Physician Fee Schedule, including a 3.3% conversion factor increase (from $32.35 to $33.42 for the non-qualifying APM base rate). That headline number is largely neutralized by a 2.5% efficiency adjustment applied to the relative value units of time-based therapy services. Net Medicare reimbursement is functionally flat, and slightly negative in some modalities.

Sellers who have shifted toward workers' compensation, personal injury, commercial insurance, and cash-pay concierge services command real premiums. They are selling a payer mix that is insulated from federal rate suppression.

One additional 2026 value enhancer: CMS finalized changes that eliminate the previous 16-day data requirement for Remote Therapeutic Monitoring reimbursement. Under the updated guidelines, a newly designated therapy RTM device code permits full reimbursement when the device is used 2 to 15 days within a 30-day monitoring period. Clinics that have integrated RTM workflows are presenting buyers with a predictable, scalable ancillary revenue line that is not constrained by clinic capacity.

Compliance and Audit Risk

The fastest way to kill a deal in 2026 is to fail diligence on compliance. Acquirers are running forensic audits on revenue cycle data, with particular focus on the KX modifier. For 2026, the therapy threshold is $2,480 combined for PT and speech-language pathology, with an independent $2,480 for OT. Billing beyond the threshold requires the KX modifier, which is an attestation of medical necessity and a magnet for federal audit attention. Clinics with abnormally high KX utilization and weak supporting documentation are walked away from.

The Department of Justice reported record False Claims Act settlement levels in 2025, and federal regulators are using data analytics to flag utilization anomalies. Buyers will require proof of annual coding audits, current HIPAA Business Associate Agreements, cyber risk assessments, and active staff compliance training. Systemic billing discrepancies, improper delegation to unlicensed aides, or unbundling will either kill the deal or drop the price by enough to escrow against future federal clawbacks.

Valuation Multiples

Lower-middle market PT and OT valuations are built on multiples of Adjusted EBITDA. The five-year historical average for outpatient PT sits at 3.6x, but that median hides enormous range. In 2026, the working spread is 2.5x to 8.0x EBITDA for lower-middle market deals, with institutional-grade platforms reaching 15.0x and beyond.

Five variables drive where you land in that range: clinic size, growth trajectory, commercial payer mix, owner dependency, and the strategic fit for the specific buyer at the table.

What Earns the Top of the Range

• Recurring or contractual revenue (workers' comp networks, industrial injury prevention contracts, school district contracts)
• Owner producing less than 20% of clinical revenue
• Diversified commercial payer mix with active in-network credentialing
• Modern EMR with clean data exports and real productivity reporting
• Tenured clinical staff with non-compete enforceability
• Geographic positioning that fills a known gap for a regional consolidator

What Compresses Multiples

• Owner producing 25% or more of clinical revenue
• Single referral source representing more than 20% of cases
• Heavy Medicare exposure with weak commercial mix
• Deferred maintenance on equipment, EMR, or facility
• Messy financials, owner add-backs that cannot be substantiated, mixed personal and business expenses
• High KX modifier utilization without supporting documentation

Deal Structure

The headline number is rarely the whole story. In 2026, buyers are routinely structuring transactions with 20% to 40% of the purchase price held back as an earnout, released over 1 to 3 years against revenue thresholds or patient retention metrics. If the seller produces more than 25% of clinical revenue, expect a binding 2 to 5 year employment agreement as a condition of closing. If the seller is purely an administrator, the transition typically compresses to a 6 to 12 month consulting arrangement focused on systems integration.

Process timeline from signed letter of intent to final closing in this diligence environment is typically 6 to 12 months.

SBA Lending & Deal Financing

For independent operators, regional MSOs, and small search funds acquiring lower-middle market PT and OT clinics in the $500K to $5M enterprise value range, the SBA 7(a) loan program is the dominant financing vehicle in 2026. The economic profile of medical clinics, recurring cash flows, localized stability, low historical default rates, makes them favored assets for SBA lenders.

The 7(a) program parameters in 2026:

• Up to $5 million in loan proceeds for business acquisition, expansion, or equipment
• Up to 10 years amortization for a standard business acquisition
• Up to 25 years if commercial real estate is bundled into the transaction
• SBA guarantees 75% to 85% of the loan amount, which improves lender willingness to extend favorable terms
• Down payment requirements often negotiated below conventional commercial loan thresholds

Q1 2026 Rate Environment

SBA 7(a) variable rates are calculated as the Wall Street Journal Prime Rate plus a maximum lender markup determined by loan size. As of early 2026, the WSJ Prime Rate is 6.75%. The SBA caps how much margin a lender can charge over Prime.

Most lower-middle market acquisitions land in the $350K+ tier, where the absolute maximum variable rate is 9.75%. In practice, lenders often price below the cap based on the borrower's credit profile, management experience, and the cash flow strength of the target clinic. The existence of these caps gives buyers genuine certainty when modeling debt service coverage, which in turn supports stronger deal structures for sellers.

For a typical SBA-financed PT or OT acquisition, the buyer is bringing 10% equity, the SBA loan is funding the bulk of the purchase price, and a seller note of 5% to 10% is common. Atlantic Coast underwrites every deal we represent against a 1.4x minimum DSCR threshold to ensure the buyer's financing is achievable before we go to market.

Timing & Market Outlook

2026 is a narrower window than it looks. Three forces are converging in a way that creates real urgency for owners considering an exit.

1. State antitrust review is about to get heavier. National consolidators are racing to close deals before state-level mini-HSR pre-merger notification laws take effect. Washington and Colorado already have expansive notification statutes. California's Senate Bill 25, the Uniform Antitrust Pre-Merger Notification Act, was passed on February 10, 2026 and takes effect January 1, 2027. Any entity required to file federally must concurrently submit documentation to the California Attorney General if it is headquartered in California or generated at least $26.78 million in state-level net sales. Critically, California's statute does not have a definitive waiting period, which creates a chaotic concurrent review environment that will extend deal timelines significantly. Similar legislation is currently pending in New York, Illinois, Hawaii, and Massachusetts.

2. Medicare relief is structurally limited. The 3.3% conversion factor increase in the 2026 MPFS sounds like good news until you recognize the 2.5% efficiency adjustment cuts directly into the time-based RVUs that PT and OT bill against. Independent operators cannot count on federal rate increases to drive growth. Sustained profitability requires economies of scale to absorb fixed administrative and technology costs, which is exactly the consolidation thesis the strategic and PE buyers are running.

3. Demographic demand is at peak inflow. Baby boomers are aging into peak utilization right now. PE sponsors are sitting on record dry powder allocated to tech-enabled healthcare platforms. The combination, peak demand, peak buyer capital, narrowing regulatory window, is what is driving the bidding tension we are seeing in Q1 2026.